47.61 0.00 (0.00%)
After hours: 5:10PM EST
|Bid||46.55 x 1100|
|Ask||47.65 x 2200|
|Day's Range||46.67 - 47.87|
|52 Week Range||35.30 - 49.22|
|Beta (3Y Monthly)||0.23|
|PE Ratio (TTM)||59.74|
|Forward Dividend & Yield||1.40 (2.98%)|
|1y Target Est||47.40|
Two Phase III CALQUENCE trials demonstrated superior progression-free survival across multiple settings while maintaining favorable tolerability
Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.
Roche's (RHHBY) breast cancer candidate and lymphona candidate get positive CHMP opinion. The company inks a deal to acquire Promedior, Inc.
Secondary endpoint of subgroup analysis showed similar rates of the composite of all-cause death, myocardial infarction or stroke between monotherapy and DAPT
Data were consistent in patients with and without type 2 diabetes, showed early effects in the first month and improvement in patient-reported outcomes
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
Announced on World Diabetes Day, the national movement will travel across America in 2020 to educate and activate communities around the connection between type 2 diabetes and hea
One of the biggest players in the Boston area’s biotech and life sciences field has snagged one of Novartis’ top dealmakers as it pushes for more early-stage collaborations.
Aravive, Inc. (ARAV) and AstraZeneca (AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of AVB-500, a GAS6/AXL inhibitor, in combination with durvalumab, a PD-L1 inhibitor, in patients with platinum-resistant, recurrent epithelial ovarian cancer has initiated and is recruiting patients. The clinical trial is jointly funded by Aravive and AstraZeneca.
Pfizer (PFE) and Merck KGaA's Bavencio misses the primary goal in a late-stage study evaluating it as the first-line maintenance therapy for patients with metastatic HER2-negative gastric cancer.
AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study. The results pit the British drugmaker's anifrolumab against rival GlaxoSmithKline Plc's Benlysta - the only new drug approved for lupus in the last 60 years. Benlysta recorded 473 million pounds of global sales in 2018, up 26% from a year earlier.
These stocks are expected to new release products or services in the next year with massive sales potential, per analysis by Bloomberg Intelligence.
Benzinga has examined the prospects for many investor favorite stocks over the past week. Benzinga continues to examine the prospects for many of the stocks most popular with investors. In "Uber Earnings Reinforce Analyst Bullishness," Elizabeth Balboa looks at why analysts remain optimistic about the prospects for Uber Technologies Inc (NYSE: UBER) despite its headwinds.
AstraZeneca said that safety data on roxadustat underpinned the British drugmaker's hopes for the anaemia drug to become a standard treatment for patients with kidney disease. It said pooled data from several late-stage trials showed that roxadustat did not increase the risk of potentially deadly cardiovascular complications like heart attacks and strokes when used instead of epo, which is the standard treatment for dialysis patients against lack of red blood cells from kidney disease. For a subgroup of patients that had just recently gone on dialysis the cardiovascular risk was about one third lower for patients on roxadustat compared with those on epo, it added.
In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® for the treatment of heart failure . The data showed that FARXIGA on top of standard of care reduced the incidence of the primary composite endpoint of cardiovascular death or worsening of HF in patients with HF with reduced ejection fraction , irrespective of the presence of chronic ...
Novo Nordisk (NVO) and Allergan (AGN) release Q3 results. FDA approves Sanofi's quadrivalent flu vaccine for older adults and Novartis' long-acting biosimilar version of Amgen's Neulasta.